Identifying causative medications for agranulocytosis: A case report of an older adult with cerebral infarction.
Yuuri KurokawaAyako WatanabeYuka KashiwabaraSaori FukudaShohei NomotoAyako KurikiKenji MomoPublished in: Clinical case reports (2024)
We present the case of a 93-year-old man who was admitted for the treatment of cerebrovascular events. The patient was initially prescribed dual antiplatelet therapy with aspirin and clopidogrel along with lansoprazole, Hange-koboku-toh, and elobixibat. On day 36 after admission, the patient was found to have developed agranulocytosis. To improve his cerebrovascular prognosis, we first discontinued medications other than the anticoagulant medicines and initiated filgrastim. We discontinued clopidogrel 9 days after the discontinuation of the other medicines considering his low white blood cell count. One day after the discontinuation of clopidogrel, the agranulocytosis was alleviated. Considering the time course, clopidogrel, lansoprazole, Hange-koboku-toh, and elobixibat were suspected as the culprit medicines. This case highlights the considerable challenges encountered in clinical practice when attempting to identify the drugs responsible for agranulocytosis, particularly in patients on intensive medication therapy.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- clinical practice
- end stage renal disease
- case report
- coronary artery disease
- chronic kidney disease
- newly diagnosed
- emergency department
- atrial fibrillation
- single cell
- venous thromboembolism
- physical activity
- cell therapy
- pulmonary embolism
- peritoneal dialysis
- cardiovascular disease
- low dose
- mesenchymal stem cells
- middle aged
- combination therapy
- adverse drug
- anti inflammatory drugs